NCT07587814Not yet recruiting
Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy
Impact de la Composition Corporelle Sur la dosimétrie de la radiothérapie Interne vectorisée au 177Lu-PSMA
Source: ClinicalTrials.gov · Last updated 14 May 2026
Brief summary (registry, in English)
COCORIVO is an interventional study evaluating the impact of body composition on dosimetry of 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Body composition (muscle, lean, visceral fat, subcutaneous fat and total fat masses) will be automatically quantified from whole-body CT images acquired at 72-96h after 177Lu-PSMA injection using the Anthropometer3DNet software. Dosimetry will be evaluated for tumors and organs at risk (salivary glands, bone marrow, kidneys). The study also evaluates the impact of body composition on SUV quantification, the feasibility of single-timepoint dosimetry, and the evolution of body composition during treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 20 Apr 2026
- Start date
- Sept 2026
- Primary completion date
- Sept 2028
- Lead sponsor
- Centre Henri Becquerel
- Diseases
- Prostate cancer
- NCT number
- NCT07587814
What you commit to
- Study type: Interventional
- Planned participants: 100
- From Sept 2026 to the primary completion date, Sept 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patient unable to understand the study or comply with study constraints (language barrier, psychological, geographic...)
- Patient under legal protection (tutelle, curatelle, sauvegarde de justice)
Who the study is looking for
- Signed informed consent
- Male, age \>= 18 years
- Histologically confirmed prostatic adenocarcinoma with multidisciplinary decision for 177Lu-PSMA treatment
- PSMA expression in tumor lesions confirmed by 68Ga-PSMA PET/CT
- Affiliated to or beneficiary of a social security scheme
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Henri Becquerel Coordinator of this site? Confirm its status | Rouen | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.